{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:17:04Z","timestamp":1780125424236,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Minnesota International Center for Antiviral Research and Epidemiology"},{"name":"University of Minnesota Foundation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["2PO1 DK 13083"],"award-info":[{"award-number":["2PO1 DK 13083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.coviro.2014.02.005","type":"journal-article","created":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T07:45:20Z","timestamp":1395215120000},"page":"1-5","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Progress, prospects, and problems in Epstein-Barr virus vaccine development"],"prefix":"10.1016","volume":"6","author":[{"suffix":"Jr.","given":"Henry H","family":"Balfour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2014.02.005_bib0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","article-title":"Epstein-Barr virus\u2014is it time to develop a vaccine program?","volume":"56","author":"Epstein","year":"1976","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2014.02.005_bib0010","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2014.02.005_bib0015","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.coviro.2014.02.005_bib0020","first-page":"889","article-title":"Smallpox vaccine: contraindications, administration, and adverse reactions","volume":"68","author":"Maurer","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.coviro.2014.02.005_bib0025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2014.02.005_bib0030","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2014.02.005_sbref0035","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.02.005_bib0040","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.coviro.2014.02.005_bib0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.176.1.169","article-title":"Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development","volume":"176","author":"Khanna","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2014.02.005_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.171.1.345","article-title":"An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3)","volume":"171","author":"Burrows","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2014.02.005_sbref0055","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.02.005_sbref0060","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2014.02.005_bib0065","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/523815","article-title":"Epstein-Barr virus vaccine for the prevention of infectious mononucleosis\u2014and what else?","volume":"196","author":"Balfour","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.02.005_bib0070","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/JVI.61.5.1416-1420.1987","article-title":"Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV\/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d","volume":"61","author":"Nemerow","year":"1987","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.02.005_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1099\/0022-1317-17-2-233","article-title":"Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro","volume":"17","author":"Moss","year":"1972","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2014.02.005_bib0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2014.02.005_bib0085","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1126\/science.276.5321.2030","article-title":"An animal model for acute and persistent Epstein-Barr virus infection","volume":"276","author":"Moghaddam","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.coviro.2014.02.005_sbref0090","doi-asserted-by":"crossref","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","article-title":"Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge","volume":"7","author":"Sashihara","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2014.02.005_sbref0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.02.005_bib0100","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1086\/491740","article-title":"A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis","volume":"192","author":"Balfour","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.02.005_bib0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","article-title":"Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder","volume":"26","author":"Holman","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.coviro.2014.02.005_bib0110","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2014.02.005_bib0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.22179","article-title":"Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya","volume":"120","author":"Rainey","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2014.02.005_bib0120","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1073\/pnas.0915054107","article-title":"HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma","volume":"107","author":"Hjalgrim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.02.005_bib0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.1980.00500510052009","article-title":"Epstein-Barr virus antibodies in multiple sclerosis","volume":"37","author":"Sumaya","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coviro.2014.02.005_bib0130","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","volume":"17","author":"Munger","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.coviro.2014.02.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2014.02.005_bib0140","doi-asserted-by":"crossref","first-page":"e1003220","DOI":"10.1371\/journal.ppat.1003220","article-title":"Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis","volume":"9","author":"Angelini","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2014.02.005_bib0145","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.coviro.2014.02.005_bib0150","doi-asserted-by":"crossref","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The need and challenges for development of an Epstein-Barr virus vaccine","volume":"31","author":"Cohen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2014.02.005_bib0155","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/infdis\/jit321","article-title":"Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition","volume":"208","author":"Balfour","year":"2013","journal-title":"J Infect Dis"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T13:22:16Z","timestamp":1597584136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625714000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":31,"alternative-id":["S1879625714000388"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2014.02.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}